Fakta om udbudet
Udbyder
Amgros I/S
Joint Nordic Procurement of Pharmaceuticals - 2022 - NF2.601.a
Amgros I/S
Contract award notice
Results of the procurement procedure
Supplies
Section I: Contracting authority
Postal address: Dampfærgevej 22
Town: København Ø
NUTS code: DK0 Danmark
Postal code: 2100
Country: Denmark
Contact person: Flemming Sonne
E-mail: udbud@amgros.dk
Telephone: +45 88713000
Fax: +45 88713008
Internet address(es):
Main address: http://www.amgros.dk
Postal address: Skaftahlíð 24
Town: Reykavik
NUTS code: IS Ísland
Postal code: 105
Country: Iceland
Contact person: Hulda Harðardóttir
E-mail: huldahar@landspitali.is
Internet address(es):
Main address: https://www.rikiskaup.is/
Postal address: Grev Wedels plass 7 5.etasje
Town: Oslo
NUTS code: NO Norge
Postal code: 0151
Country: Norway
Contact person: Eirik Sverrisson
E-mail: legemidler@sykehusinnkjop.no
Internet address(es):
Main address: https://sykehusinnkjop.no/
Danish Law
Section II: Object
Joint Nordic Procurement of Pharmaceuticals - 2022 - NF2.601.a
Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award framework agreements in order to ensure the supply of pharmaceuticals to the public hospitals and health authorities in the countries. In Denmark certain pharmaceuticals are resold to the Faroe Island and Greenland.
The obligation to deliver the pharmaceuticals in Iceland is subject to the precondition that the supplier obtains an exemption regarding printed labels and leaflets. If the supplier does not obtain such exemption the agreement will only apply to Denmark and Norway, see the Framework agreement section 2.2.1 and Appendix 6.
The framework agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the framework agreement.
1
ATC Code: J01CA01
Generic name: Ampicilline
Pharmaceutical form: Injection fluid
Strength: 1 g
Unit: 6 g
Volume in units: (Denmark 12.525) (Norway: 12.646) (Iceland: 3.166)
ATC Code: J01CA01
Generic name: Ampicilline
Pharmaceutical form: Injection fluid
Strength: 2 g
Unit: 6 g
Volume in units: (Denmark 47.579) (Norway: 149.333) (Iceland: 10)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. Reference is made to the tender specifications, including the provision on the list of products in general.
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”) and the Norwegian “Farmalogg” and the Icelandic “Lyfjaverðskrá” not later than 7 February 2022 in order to ensure supply from the beginning of the Purchase Period.
Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The two options may be exercised on the terms and conditions stipulated in the framework agreement.
for
2
Procurement no.: 2
ATC Code: J01DC02
Generic name: Cefuroxime
Pharmaceutical form: Duplex infusionbag
Strength: 1500 mg
Unit: 3 g
Volume in units: (Denmark 104.928) (Norway: 12.000) (Iceland: 10)
ATC Code: J01DC02
Generic name: Cefuroxime
Pharmaceutical form: Duplex infusionbag
Strength: 750 mg
Unit: 3 g
Volume in units: (Denmark 31.692) (Norway: 1.200) (Iceland: 10)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. Reference is made to the tender specifications, including the provision on the list of products in general.
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”) and the Norwegian “Farmalogg” and the Icelandic “Lyfjaverðskrá” not later than 7 February 2022 in order to ensure supply from the beginning of the Purchase Period.
Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The two options may be exercised on the terms and conditions stipulated in the framework agreement.
for
3
Procurement no.: 3
ATC Code: J01DD02
Generic name: Ceftazidime
Strength: 1 g
Unit: 4 g
Volume in units: (Denmark 1.625) (Norway: 4.000) (Iceland: 580)
ATC Code: J01DD02
Generic name: Ceftazidime
Strength: 2 g
Unit: 4 g
Volume in units: (Denmark 7.050) (Norway: 25.000) (Iceland: 2.010)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. Reference is made to the tender specifications, including the provision on the list of products in general.
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”) and the Norwegian “Farmalogg” and the Icelandic “Lyfjaverðskrá” not later than 7 February 2022 in order to ensure supply from the beginning of the Purchase Period.
Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The two options may be exercised on the terms and conditions stipulated in the framework agreement.
for
4
Procurement no.: 4
ATC Code: J01DD04
Generic name: Ceftriaxone
Strength: 1 g
Unit: 2 g
Volume in units: (Denmark 9.520) (Norway: 4.150) (Iceland: 5.666)
ATC Code: J01DD04
Generic name: Ceftriaxone
Strength: 2 g
Unit: 2 g
Volume in units: (Denmark 56.980) (Norway: 60.200) (Iceland: 4.231)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. Reference is made to the tender specifications, including the provision on the list of products in general.
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”) and the Norwegian “Farmalogg” and the Icelandic “Lyfjaverðskrá” not later than 7 February 2022 in order to ensure supply from the beginning of the Purchase Period.
Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The two options may be exercised on the terms and conditions stipulated in the framework agreement.
for
5
Procurement no.: 5
ATC Code: J01GB03
Generic name: Gentamicine
Strength: 1 mg/ml
Unit: 0,24 g
Volume in units: (Denmark 1.940) (Norway: 17.166) (Iceland: 400)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. Reference is made to the tender specifications, including the provision on the list of products in general.
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”) and the Norwegian “Farmalogg” and the Icelandic “Lyfjaverðskrá” not later than 7 February 2022 in order to ensure supply from the beginning of the Purchase Period.
Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The two options may be exercised on the terms and conditions stipulated in the framework agreement.
for
6
Procurement no.: 6
ATC Code: J01GB03
Generic name: Gentamicine
Strength: 3 mg/ml
package: 80 ml
Unit: 0,24 g
Volume in units: (Denmark 24.580) (Norway: 62.620) (Iceland: 1.100)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. Reference is made to the tender specifications, including the provision on the list of products in general.
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”) and the Norwegian “Farmalogg” and the Icelandic “Lyfjaverðskrá” not later than 7 February 2022 in order to ensure supply from the beginning of the Purchase Period.
Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The two options may be exercised on the terms and conditions stipulated in the framework agreement.
for
7
Procurement no.: 7
ATC Code: J01GB03
Generic name: Gentamicine
Strength: 3 mg/ml
package: 120 ml
Unit: 0,24 g
Volume in units: (Denmark 13.110) (Norway: 86.820) (Iceland: 1.350)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. Reference is made to the tender specifications, including the provision on the list of products in general.
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”) and the Norwegian “Farmalogg” and the Icelandic “Lyfjaverðskrá” not later than 7 February 2022 in order to ensure supply from the beginning of the Purchase Period.
Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The two options may be exercised on the terms and conditions stipulated in the framework agreement.
for
8
Procurement no.: 8
ATC Code: J01MA02
Generic name: Ciprofloxacin
Pharmaceutical form: Infusion fluid
Strength: 2 mg/ml
package: 100 ml
Unit: 0,8 g
Volume in units: (Denmark 9.860) (Norway: 4.605) (Iceland: 60)
ATC Code: J01MA02
Generic name: Ciprofloxacin
Pharmaceutical form: Infusion fluid
Strength: 2 mg/ml
package: 200 ml
Unit: 0,8 g
Volume in units: (Denmark 50.230) (Norway: 28.570) (Iceland: 1000)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. Reference is made to the tender specifications, including the provision on the list of products in general.
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”) and the Norwegian “Farmalogg” and the Icelandic “Lyfjaverðskrá” not later than 7 February 2022 in order to ensure supply from the beginning of the Purchase Period.
Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The two options may be exercised on the terms and conditions stipulated in the framework agreement.
for
9
Procurement no.: 9
ATC Code: J01XA01
Generic name: Vancomycin
Pharmaceutical form: Infusion fluid
Strength: 500 mg
package:
Unit: 2 g
Volume in units: (Denmark 25.257) (Norway: 4.718) (Iceland: 10)
ATC Code: J01XA01
Generic name: Vancomycin
Pharmaceutical form: Infusion fluid
Strength: 1000 mg
package:
Unit: 2 g
Volume in units: (Denmark 79.377) (Norway: 60.430) (Iceland: 9.832)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. Reference is made to the tender specifications, including the provision on the list of products in general.
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”) and the Norwegian “Farmalogg” and the Icelandic “Lyfjaverðskrá” not later than 7 February 2022 in order to ensure supply from the beginning of the Purchase Period.
Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The two options may be exercised on the terms and conditions stipulated in the framework agreement.
for
10
Procurement no.: 10
ATC Code: J01XD01
Generic name: Metronidazol
Pharmaceutical form: Infusion fluid
Strength: 5 mg/ml
package:
Unit: 1,5 g
Volume in units: (Denmark 293.320) (Norway: 152.207) (Iceland: 10.333)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. Reference is made to the tender specifications, including the provision on the list of products in general.
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”) and the Norwegian “Farmalogg” and the Icelandic “Lyfjaverðskrá” not later than 7 February 2022 in order to ensure supply from the beginning of the Purchase Period.
Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The two options may be exercised on the terms and conditions stipulated in the framework agreement.
for
Section IV: Procedure
Section V: Award of contract
1
National registration number: 13902992
Postal address: Marielundvej 46 A
Town: Herlev
NUTS code: DK0 Danmark
Postal code: 2730
Country: Denmark
Section V: Award of contract
2
Section V: Award of contract
3
National registration number: 21347809
Postal address: Islands Brygge 57
Town: Copenhagen
NUTS code: DK0 Danmark
Postal code: 2300
Country: Denmark
Section V: Award of contract
4
National registration number: 21347809
Postal address: Islands Brygge 57
Town: Copenhagen
NUTS code: DK0 Danmark
Postal code: 2300
Country: Denmark
Section V: Award of contract
5
National registration number: 20343249
Postal address: Dirch Passers Alle 27, 3. sal
Town: Frederiksberg
NUTS code: DK0 Danmark
Postal code: 2000
Country: Denmark
Section V: Award of contract
6
National registration number: 20343249
Postal address: Dirch Passers Allé 27, 3. sal
Town: Frederiksberg
NUTS code: DK0 Danmark
Postal code: 2000
Country: Denmark
Section V: Award of contract
7
Postal address: Dirch Passers Alle 27, 3. sal
Town: Frederiksberg
NUTS code: DK0 Danmark
Postal code: 2000
Country: Denmark
Section V: Award of contract
8
Postal address: Göteborgsvägen 74
Town: Göteborg
NUTS code: SE Sverige
Postal code: 433 63
Country: Sweden
Section V: Award of contract
9
Postal address: Kirkeler Str. 41
Town: Blieskastel-Niederwuerzbach
NUTS code: DE300 Berlin
Postal code: 66440
Country: Germany
Section V: Award of contract
10
National registration number: 72246012
Postal address: Tobaksvejen 2A
Town: Søborg
NUTS code: DK0 Danmark
Postal code: 2860
Country: Denmark
Section VI: Complementary information
This call for tenders is conducted as an open procedure in accordance with the Danish Procurement Act (udbudsloven). The procurement procedure is subject to Danish law and any complaints of the procurement procedure shall be lodged with the Danish Complaints Board for Public Procurement (Klagenævnet for udbud),see section VI.4.3.
In relation to section II.2.4, it should be noted, that the Contracting Authorities have considered whether the procurement group could be further subdivided. The Contracting Authorities have deemed that this is not the case based on the considerations of economies of scale, which will not be realizable with a further subdivision as well as costs and patient safety considerations related to the subsequent management of contract- and pharmaceuticals.
In relation to sections II.1.5 and II.2.6 it should be noted that the estimated value indicated in section II.1.5 is the total estimated value of all procurement numbers (lots) for the duration of the framework agreement, including the option of renewal, see section II.2.7. Section II.2.6 sets out the estimated value for each procurementnumber, including the option of renewal, see section II.2.7. The value is based on the AIP ("ApotekernesIndkøbspris" published by the Danish Medicines Agency) of the pharmaceuticals. It should furthermore be noted that the estimated value is based on historic consumption data and that the actual purchase under aframework agreement may deviate significantly from the estimate, see section II.2.4, paragraph 5.6 of the tender specifications and clause 4.2 of the framework agreement.
Questions concerning the tender documents must be submitted through the tendering system, see the provisions of the tender specifications in this regard.
The access to submit tender requires that the operator is registered as a user of Amgros' tendering system. The registration as a user may take a few days, and the tenderer must therefore make sure to register in good time. Reference is made to the information provided in the tendering system, including the user guide.
In relation to section VI.2 it should be noted that electronic invoicing is required.
Postal address: Nævnenes Hus, Toldboden 2
Town: Viborg
Postal code: 8800
Country: Denmark
E-mail: klfu@naevneneshus.dk
Telephone: +45 72405600
Internet address: https://klfu.naevneneshus.dk
Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no. 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:
Complaints of the tendering procedure must be lodged with the Complaints Board for Public Procurement within6 months after the contracting entity has entered into a framework agreement calculated from the day after the day when the contracting entity has notified the affected applicants and tenderers, see section 7(2), para.(3) of the Act. Not later than at the time of lodging a complaint with the Danish Complaints Board for Public Procurement, the complainant must notify the contracting authorities in writing that a complaint has been lodged with the Danish Complaints Board for Public Procurement and whether the complaint was lodged during the standstill period, see section 6(4) of the Act. In cases where the complaint was not lodged within the standstill period, the complainant must furthermore indicate whether a suspensory effect of the complaint has been requested, see clause 6(4) of the Act.
Postal address: Carl Jacobsens vej 35
Town: Valby
Postal code: 2500
Country: Denmark
Telephone: +45 41715000
Internet address: http://www.kfst.dk
BREAKING